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Intravesical instillation of bacillus Calmette–Guérin (BCG) is used to treat superficial
bladder cancer, either papillary tumors (after transurethral resection) or high-grade flat
carcinomas (carcinoma in situ), reducing recurrence in about 70% of patients. Initially,
BCG was proposed to work through an inflammatory response, mediated by phagocytic
uptake of mycobacterial antigens and cytokine release. More recently, other immune
effectors such as monocytes, natural killer (NK), and NKT cells have been suggested
to play a role in this immune response. Here, we provide a comprehensive study of
multiple bladder cancer cell lines as putative targets for immune cells and evaluated their
recognition by NK cells in the presence and absence of BCG. We describe that different
bladder cancer cells can express multiple activating and inhibitory ligands for NK cells.
Recognition of bladder cancer cells depended mainly on NKG2D, with a contribution from
NKp46. Surprisingly, exposure to BCG did not affect the immune phenotype of bladder
cells nor increased NK cell recognition of purified IL-2-activated cell lines. However, NK
cells were activated efficiently when BCG was included in mixed lymphocyte cultures,
suggesting that NK activation after mycobacteria treatment requires the collaboration of
various immune cells. We also analyzed the percentage of NK cells in peripheral blood
of a cohort of bladder cancer patients treated with BCG. The total numbers of NK cells
did not vary during treatment, indicating that a more detailed study of NK cell activation
in the tumor site will be required to evaluate the response in each patient.
Keywords: natural killer cells, NKG2D, natural cytotoxicity receptors, Mycobacterium bovis, bladder cancer
Introduction
Intravesical instillation with Bacillus Calmette–Guérin (BCG), a live attenuated form of Mycobac-
terium bovis, is a first choice therapy for high-grade superficial bladder cancer, such as carcinoma
in situ (CIS), and it is also used as an adjuvant, following transurethral resection (TUR), in
papillary non-muscle invasive bladder cancer (NMIBC) (1). Due to the efficiency of this therapy,
multiple studies on its mechanism of action have been published in the last decade [reviewed in
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Ref. (2)]; however, a full understanding of how BCG therapy
works has still not been achieved (3). A detailed knowledge of the
molecular basis of this therapy would be valuable since exposure
to the bacteria can also produce undesired adverse effects and the
ability to identify non-responder patients at an early stage would
allow clinicians to switch to alternative therapies earlier in the
disease. A considerable body of experimental evidence indicates
that natural killer (NK) and NKT cells play an important role on
the anti-tumor responses induced by BCG in the treatment of
superficial bladder carcinoma (4–9). For this reason, it is impor-
tant to study in detail the characteristics of the immune response
mediated by these cells.
Natural killer cells usually represent 5–15% of peripheral blood
lymphocytes and respond to their targets without prior antigen
sensitization; in particular, their activity is important against
virus-infected cells and tumor cells [for review, see Ref. (10)]. NK
cell cytotoxicity is exerted by release of lytic granules toward the
target cell after formation of a cytotoxic immunological synapse,
but, instead of depending on a single receptor, like the TCR in T
cells,NK cells require the integration of signals produced by a large
number of activating and inhibitory receptors [for review, see Ref.
(11, 12)]. In this context, while recognition ofMHC-I can be a very
strong inhibitory signal, activation mediated by certain activating
receptors and cytokines can override the recognition of MHC.
The presence of different receptors at the NK cell surface defines
several NK subsets with different functional properties. Therefore,
to understand how NK cells respond against bladder tumors, in
the context of BCG, it is necessary to dissect the contribution of
different receptors to NK cell recognition of these tumor cells.
Previous data show thatNK cells could kill one urothelial tumor
cell line, T24 (6, 7) and that effector cells could be recognizing
NKG2D ligands on this cell line (9); however, the presence of these
ligands in bladder cancer cells has not been previously explored.
The purpose of the work presented here was to systematically
evaluate the contribution of immune activating and inhibitory
ligands to bladder cancer recognition by NK cells in the context
of BCG immunotherapy. We report a comprehensive analysis of
the immune phenotype of a panel of urothelial tumor cells and
their differential ability to be lysed by primary NK cell lines from
healthy donors. We identify NKG2D as a key receptor involved
in the recognition of bladder cancer cells by activated NK cells,
while NKp46 only contributes partially to the response against
certain bladder cell lines. The exposure of purified NK cells to
BCG does not affect NK function; however, activation of NK
cells can be achieved by exposing PBMCs to BCG. Initial analysis
of peripheral blood obtained from BCG-treated bladder cancer
patients included in a pilot study show more differences in the
percentage of NK cells among individuals than in response to
treatment. We have also analyzed the amount of NKG2D receptor
in the surface of different subpopulations of NK cells.
Materials and Methods
Reagents
Antibodies
Monoclonal antibodies specific for ULBP1, 2, 3, MICA, and
MICB were purchased from R&D Systems (Abingdon, UK);
ICAM-1/CD54 (Immunotech, Clone 84H10); Nectin 2/CD112
(Santa Cruz, Clone B-C12); CD155/PVR (Abcam, Clone
D171); E-Cadherin (Immunotech, Clone 67A4); CD58/LFA-3
(Immunotech, Clone AICD58); CD106/VCAM-1 (Pharmingen,
Clone 51-10C9); CD48 (Diaclone, Clone MEM102). MHC class
I specific antibody [HP-1F7 (13)] and L31 anti-HLA-C antibody
(14) were previously described. Conjugated antibodies for blood
lymphocyte subpopulations were from Biolegend and Immuno-
tools. Secondary antibodies, such as FITC- and PE-conjugated
anti-mouse Ig, were purchased from DakoCytomation. Blocking
antibodies, specific for anti-human NKG2D (clone 149810),
NKp46/NCR1 (clone 195314), NKp30/NCR3 (clone 210845),
and DNAM-I/CD226 (clone 102511), were purchased from
R&D. KLRG1 antibody was kindly provided by Prof. H. Pircher
(University Medical Center Freiburg).
Fusion proteins of NKp46 and NKp30 were prepared by
exchanging the human Fc portion of the constructs previously
described (15, 16) with a murine IgG1 Fc, to minimize possi-
ble Fc/Fc receptor interactions during flow cytometry of human
cells. Stable transfectants secreting recombinant proteins were
produced in HEK293FT cells (Life Technologies) maintained
in DMEM 4.5mg/l glucose medium supplemented with 10%
FBS, -Glutamine, non-essential amino acids, sodium pyruvate,
and antibiotics (penicillin/streptomycin), and 1µg/ml puromycin.
NKG2D-Fc constructs, prepared by transient transfection in 293T
cells, have been previously described (17).
BacillusCalmette–GuérinTice strain (fromMerckCanada Inc.)
was used for the majority of the experiments. For some experi-
ments, the strains Connaught (from Sanofi Pasteur Limited) and
Danish 1331 (kindly provided by Pfizer) were used. Aliquots of
reconstituted BCG were prepared and stored at 20°C.
Cell Lines and Peripheral Blood Subpopulations
The bladder cancer cell lines T24, UM-UC-3, J82, RT-112, RT4,
and SW780 are available from the ATCC [cell lines were kindly
provided by Dr. FX Real (CNIO, Madrid) and genotyped using
the StemElite ID System (Promega) at the Genomics Service (IIB-
CSIC)]. Cells were grown in EMEM medium (Lonza) supple-
mented with 10% FCS, 1mM glutamine, 1mM sodium pyru-
vate, 0.1mM non-essential amino acids, 100U/ml penicillin, and
100U/ml streptomycin (Biowest).
Polyclonal NK cell lines were prepared from healthy volunteer
buffy coats [(Regional Transfusion Centre, Madrid), approval
from local ethical committees and informed consent from all
participants were obtained; experiments have been conducted
according to the principles expressed in the Declaration of
Helsinki]. PBMCs were isolated by centrifugation on Ficoll-
HyPaque. NK cells were isolated by negative selection using the
MACS NK Cell Isolation Kit (Miltenyi Biotec) and cultured in
the presence of irradiated feeder cells (autologous PBMCs, Daudi
and RPMI-8866 B cell lines) in RPMI-1640 medium (Lonza)
supplementedwith 10%FBS, 10%maleABnegative human serum
(the first week, and later with 5% FBS, 5% Human Serum),
4mM -glutamine, 0.1mM non-essential amino acids, 1mM
sodium pyruvate, 100U/ml penicillin, 100U/ml streptomycin,
10mMHepes, 50µM β-mercaptoethanol (Biowest), and 50 IU/ml
rhlL-2 (Peprotech). Greater than 95% pure NK cell cultures were
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re-stimulated weekly and the NK phenotype was monitored by
flow cytometry. Functional experiments with NK cells were per-
formed 4–5 days after IL-2 stimulation. Freshly isolated NK cells,
after MACS purification, were maintained in culture, without
rhIL-2, with or without BCG, up to 2 days, before use in experi-
ments.
K562, Daudi, and RPMI-8866 cells were grown in RPMI-1640
medium (Lonza) supplementedwith 10%FBS, 4mM-glutamine,
0.1mM non-essential amino acids, 1mM sodium pyruvate,
100U/ml penicillin, 100U/ml streptomycin, and 10mMHepes.
For experiments using mixed culture of lymphocytes, PBMCs
were incubated for a week in the presence or absence of BCG
in RPMI with 5% FBS, 5% Human Serum, 4mM -glutamine,
0.1mM non-essential amino acids, 1mM sodium pyruvate,
100U/ml penicillin, 100U/ml streptomycin, 10mM Hepes, and
50µM β-mercaptoethanol (Biowest).
Flow Cytometry
Cells were incubated with the appropriate primary antibodies
or receptor-Fc fusion proteins, followed by either PE- or FITC-
labeled F(ab0)2 fragments of goat anti-mouse Ig (Dako) or PE-
labeled F(ab0)2 fragments of goat anti-human Fc (Immunotech),
or directly with the conjugated antibodies. Samples were ana-
lyzed using BD FACSCalibur (Becton Dickinson), Gallios Flow
Cytometer or Cytomics FC 500 (Beckman Coulter). Analysis of
the experiments was performed using the Kaluza, Summit, or
FlowJo softwares.
Degranulation Assays
Natural killer cells were co-cultured with target cells for 2 h at
an E:T ratio of 1:2. Surface expression of LAMP-1 (CD107a) was
analyzed by flow cytometry. In experiments where NK cell recep-
tors were blocked, mAb were included in the medium to a final
concentration of 5µg/ml for 20min, prior to co-incubation with
target cells. In the experiments where MHC class I was blocked,
the specific antibody (HP-1F7) was included in the medium at a
final concentration of 10µg/ml for 30min. K562 cells were used
as positive control targets.
Measurement of IFNγ Production
Natural killer cells were co-cultured with target cells for 6 h at
37°C 5% CO2 at an E:T ratio of 1:2. After 1 h of co-incubation,
monensin was added to a final concentration of 2.5µM. After
6 h, cells were recovered, fixed with 2% p-formaldehyde at RT for
10min, permeabilized with 0.2% saponin at RT for 10min, and
intracellular IFNγ was analyzed by flow cytometry.
Cytotoxicity Assays
Bladder cancer cells were plated in triplicates at 1.5 105 cells/ml,
in a final volume of 1ml, and labeled for 16 h with calcein AM
(Molecular Probes, C3100MP) at 0.5µg/ml. Cells were washed
and incubated in fresh medium for 2 h. NK cells were co-cultured
with target cells for 4 h at 37°C 5% CO2, at the indicated E:T
ratios. Assays were terminated by collection of the supernatant
from the co-culture, centrifugation at 200 g for 5min to elim-
inate remaining cells and collection of the new supernatant.
Calcein release was determined by using EnVision® Multilabel
Reader, with these measurement parameters: excitation wave
486 nm and emission wave 530 nm. Specific lysis was expressed
as percentage, calculated as the ratio [(value  spontaneous
release)/(maximum  spontaneous release)] 100. Spontaneous
release was determined by incubation of the labeled target cells
alone. Maximum release was determined by lysing the target cells
in 0.1% SDS. In all the experiments, the spontaneous release was
<25% of maximum release. Each experiment was repeated two
to five times. Error was <5% of the mean of the triplicates. In
blocking experiments, mAb was included to a final concentration
of 5µg/ml. K562 cells were used as positive control targets.
Patient Samples
Blood was obtained from a cohort of bladder cancer patients
(Ta/T1 G3 or CIS, mean age 72.8) receiving BCG instillations,
at different times during treatment at Hospital Infanta Sofía
(Madrid, Spain). As a control, bladder cancer patients (Ta/T1
G2, mean age 70.1) receiving mitomycin C (MMC) instillations
were recruited. The experiments were conducted with the under-
standing and the consent of each participant and approved by
local and regional ethical committees (CEIC La Paz Hospital, CEI
Infanta Sofía Hospital, and CSIC Local Ethical Committee). One
hundred microliters of blood were analyzed by flow cytometry
for the expression of CD56, NKG2D, and NKp46 using a Gallios
Flow cytometer and Kaluza software. Data processing was per-
formed creating an algorithm to compile information for further
statistical analysis using the GraphPad Prism 6 package. Statistical
significance was assessed using multiple T-tests and corrected for
multiple comparisons using the Sidak–Bonferroni method.
Results
Bladder Cancer Cells can Express Different
Combinations of Immune Ligands
To characterize the ability of bladder cancer cells to stimulate
NK cell responses, a panel of urothelial tumor cells with dif-
ferent grades of differentiation (T24, UM-UC-3, J82, RT-112,
RT4, SW780) were stained with antibodies against different NK
ligands for flow cytometry analysis. Three groups of molecules
were checked: ligands for activating receptors, inhibitory ligands,
and adhesion molecules involved in NK recognition. Figure 1
shows representative flow cytometry profiles and Figure S1 in
Supplementary Material the statistical analysis of all the markers
studied. For simplicity, FACS data and grade of tumor cell lines
are summarized inTable 1. Notably, different urothelial cells show
different patterns of immune ligands aswell asMHCand adhesion
molecules, suggesting that their susceptibility to NK cell lysis
could be different.
All the cell lines analyzed expressed different levels of NKG2D
ligands, all of which could contribute to the activation of NK cells.
While all the cell lines showed low to medium levels of surface
ULBP2 and ULBP3 (except UM-UC-3, that only had low levels
of ULBP3), none of them expressed ULBP1; MICA surface levels
show very different pattern among the different cell lines and
MICB expression was not significant in any of the cell lines. To
check for the capacity of each cell line for binding the NKG2D
receptor, NKG2D-Fc constructs were used to stain the bladder
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FIGURE 1 | Expression of ligands for NK cells on bladder cancer
cell lines. The indicated bladder cell lines were stained with antibodies
specific for several NKG2D ligands (A), surface MHC, using the
pan-MHC antibody HP1F7 (B) and the adhesion molecules E-cadherin
and CD54 (C), and analyzed by flow cytometry. The figure shows a
representative experiment out of more than five for each molecule. For
more markers and statistical analysis, see Table 1 and Figure S1 in
Supplementary Material.
cell lines (Figure S2 in Supplementary Material). Other activating
ligands were also present at low amounts in urothelial cancer
cells, like NKp30-ligand and variable amounts of NKp46-ligand
(Figure S3 in Supplementary Material). The activating receptor
2B4 is present in most NK cells; however, its ligand CD48 was not
detected in any of the bladder cell lines analyzed.
MHC plays an important role in NK cell inhibition, thus, the
levels of total surface MHC and, in particular, HLA-C was also
analyzed. Again, different levels were found on the different cell
lines, J82 expressing highest amounts of MHC-I while the rest
of the cell lines had lower levels. The amount of MHC observed
at the cell surface of UM-UC-3 and RT-112 was very low or
absent.
Although E-cadherin is an adhesionmolecule, playing a pivotal
role in Ca2+-dependent cell-cell adhesion and contributing to
tissue organization and development, it has been shown to bind
the killer cell lectin-like receptor G1 (KLRG1) that belongs to
the C-type lectin-like superfamily and contains an ITIM in its
cytoplasmic domain (23). T24, UM-UC-3, and J82 did not express
surface E-cadherin, suggesting that this inhibitory interaction will
not occur, while less dedifferentiated cell lines expressed this
molecule. However, around 50% of IL-2-cultured NK cells did not
express this receptor (data not shown), consistent with published
data (24, 25).
Other surface molecules that could contribute to NK cytotox-
icity were also analyzed. CD54 (ICAM-1, intercellular adhesion
molecule-1) binds β2 integrins (such as LFA-1) and is crucial for
the formation of conjugates (26, 27). All the bladder tumor cell
lines analyzed expressed at least low amounts of ICAM-1 at the
surface, suggesting that they all have what has been suggested as
the minimal requirement for adhesion. However, different lev-
els of expression could modulate the response. All bladder cells
also expressed different amounts of CD112, CD155, and CD58.
CD112 (Nectin-2, PVRL2) and CD155 (Necl5, PVR) bind CD226
(DNAM-1), which potentiates in vitro the cytotoxicity of NK
cells against a wide range of tumor cells (28, 29); CD58 (LFA-3)
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TABLE 1 | Cell surface expression of activating and inhibitory ligands by bladder cancer cells.
T24b UM-UC-3c J82d RT-112e RT4e SW780f
Tumor gradea 3 3 3 2 1 1
Activating and inhibitory
ligands for NK receptors
MICA + + +++   + ++
ULBP1            
ULBP2 ++ + ++ ++ + ++
ULBP3 ++ + + ++ ++ ++
NKp46L ++ + + ++   +
NKp30L + + + + + +
E-CADHERIN       ++ ++ ++
CD48            
MHC ++ + +++   + ++
HLA C ++ + +++   +++ +
Adhesion molecules CD54/ICAM-1 ++ + +++ + + +
CD112/NECTIN ++ + ++ + + ++
CD155 ++ ++ ++ +++ ++ +++
CD58/LFA3 ++ ++ ++ +++ ++ ++
CD106/VCAM-1            
Data summarize MFI values shown in Figure S1 in Supplementary Material.
aSource of tumor grade information: see reference beside each cell line name.
bBubenik et al. (18).
cGrossman et al. (19).
dO’Toole et al. (20).
eMasters et al. (21).
fKyriazis et al. (22).
FIGURE 2 | Recognition of bladder cancer cells by IL-2-activated
NK cells. (A) Degranulation experiments. NK cells were incubated for 2 h
with the indicated bladder cancer cells, pre-incubated with anti-MHC-I
antibody, at an E:T ratio of 1:2 and surface LAMP-1 (CD107a) was
analyzed by flow cytometry. (B) IFNγ production. NK cells were incubated
with bladder cancer cells, blocked for MHC-I, for 6 h in the presence of
monensin (2.5µM) at an E:T ratio of 1:2 and IFNγ production was analyzed
by flow cytometry. (C) Cytotoxicity experiments. Target cells were labeled
with calcein for 16 h, washed and incubated for 4 h with NK cells at an E:T
ratio of 10:1. Specific calcein release was measured in supernatants and
the percentage of cytotoxicity calculated. Symbols represent results
obtained with NK cells obtained from different donors.
binds CD2 and its co-engagement with ICAM-1 increases NK
response (30).
None of the cell lines analyzed expressed surface CD106
(VCAM, vascular cell adhesion molecule), which strongly binds
α4β1 integrins on lymphocytes (31).
In light of these data, different bladder cancer cell lines have
several potential ligands to activate and inhibit NK cells and, since
a large number of signals will need to be integrated it is difficult to
predict the ability of each cell line to stimulate NK cell activation.
Recognition of Different Bladder Cell Lines by NK
Cells Depends Mainly on NKG2D
Preliminary experiments showed that freshly isolated NK cells
responded poorly to bladder cancer cells (data not shown). Thus,
primary IL-2-activated NK cell lines were prepared from healthy
donors and used as effector cells in degranulation experiments
against the panel of bladder cancer cells. Figure 2A shows
the percentage of NK cells that expressed LAMP-1 (CD107a)
at the plasma membrane after contact with the target cell, a
marker present in cytotoxic granules that allows identification
of those cells that have activated the degranulation machinery.
As expected from the variety of activating and inhibitory lig-
ands expressed at the surface of different bladder cancer cell
lines, NK cells responded differently to the panel of cell lines.
Experiments were performed with NK cells prepared from a
large number of donors to evaluate donor to donor variation.
T24, UM-UC-3, and J82 were consistently better able to stim-
ulate NK degranulation than RT-112, RT4, and SW780 with
all the donors tested. The cell lines that stimulated the highest
amount of degranulation were also most efficient in triggering
IFNγ production (Figure 2B). However, all the bladder tumor
cell lines, except RT-112, were killed efficiently in cytotoxicity
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assays (Figure 2C). This may reflect the involvement of non-
lytic granule-dependent mechanisms of cytotoxicity, e.g., FAS or
TRAIL-mediated death in causing the death of the RT-112, RT4,
and SW780 cell lines.
Although the cytotoxicity results could be explained in part by
the presence ofNKG2D ligands at the cell surface, othermolecules
probably play also a role. In order to identify NK receptors
involved in the recognition of urothelial cells by primary activated
NK cell lines, antibody blocking was performed in degranulation
experiments. As shown in Figure 3A, NKG2D clearly contributed
strongly to the recognition of bladder cancer cells while NKp46
had an additive role only in some of these cells probably due to
the balance of signals. By contrast, addition ofNKp30 orDNAM-1
blocking antibodies did not further enhance NKG2D blocking.
Cytotoxicity experiments confirmed the importance of NKG2D
for the recognition of bladder cancer cells (Figure 3B).
The contribution of inhibition mediated by recognition
of MHC was also tested in experiments blocking MHC-I
(Figure 3C). Although the cells expressing higher levels of MHC-
I were recognized somewhat more efficiently after blockade, the
loss of MHC inhibitory signals did not change the pattern of
degranulation toward the different bladder cancer cells. Thus,
these data confirmed that the variability on the lysis susceptibility
among different bladder cell lines was independent of donor, and
suggested that the lack of degranulation toward several of the cell
lines did not depend on missing-self recognition.
A possible inhibitory effect of E-cadherin expression on NK
cell recognition could be excluded since mAb-mediated blockade
FIGURE 3 | Receptors involved in the recognition of bladder cancer
cells by IL-2-activated NK cells. (A) The effect of activating receptor
blockade was studied in degranulation experiments measuring surface
LAMP-1 (CD107a) by flow cytometry. NK cells were pre-incubated with
antibodies against the indicated receptors before the co-incubation with
bladder cancer targets for 2 h at an E:T ratio of 1:2. (B) The effect of
NKG2D blockade was also analyzed in cytotoxicity experiments measuring
specific calcein release from bladder target cells. Target cells were labeled
with calcein for 16 h, washed and incubated for 4 h with NK cells at an E:T
ratio of 10:1. Specific calcein release was measured in supernatants and
the percentage of cytotoxicity calculated. (C) The effect of MHC blockade
was studied in degranulation experiments measuring surface LAMP-1 by
flow cytometry. Each panel shows values of several independent
experiments for each cell line.
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of KLRG1 had very little effect on NK degranulation (data not
shown).
Exposure of Bladder Cells to BCG did not Affect
Susceptibility to NK Lysis
After intravesical instillation of BCG in bladder cancer patients,
mycobacteria first contact with the bladder epithelium and some
reports indicate that urothelium could contribute to immune
modulation. For example, urothelial cells have been shown to
release cytokines after contact with Escherichia coli Hu734 (32)
and to express toll-like receptors (33). In other experiments,
exposure to Mycobacterium tuberculosis (Mtb) increased surface
expression of one of the NKG2D-L (34). For these reasons, we
investigated whether exposure to BCG affected the presence of
NKG2D ligands on the surface of a panel of bladder cancer cell
lines. Cells were initially treated with BCG for 1 and 4 days and no
major changes were observed in the expression of NKG2D ligands
(Figure 4A), then longer times were analyzed and, up to day 7 no
FIGURE 4 | Effect of BCG exposure on bladder cancer cell lines.
(A) Bladder cancer cell lines T24, RT-112, J82 were incubated in the
presence of BCG (two bacteria per bladder cell) for the indicated times
and analyzed by flow cytometry for the expression of NKG2D-L and
MHC. Data show the average and SD of three independent experiments.
(B) Degranulation experiments. Bladder cancer cell lines T24, RT-112,
J82 were incubated in the presence of BCG for the indicated times and
blocked with anti-MHC-I antibody before being co-incubated with NK
cells for 2 h at an E:T ratio of 1:2. Data show the average and SD of three
independent experiments.
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FIGURE 5 | Effect of BCG exposure on IL-2-activated NK cells. The
ability of BCG-exposed NK cells to respond to bladder cancer cells was
analyzed in degranulation experiments measuring surface LAMP-1 (CD107a)
by flow cytometry. NK cells were incubated with BCG (1:1) for 4 days and
used as effectors in degranulation assays with the indicated bladder cancer
cells blocked with anti-MHC-I antibody. Data show the average and SD of
three independent experiments.
differences were observed (data not shown). Since it is difficult to
estimate how many bacteria encounters each bladder cell during
treatment, the experiments were performed using several ratios of
BCG:bladder cells (1:1–10:1) and no difference in surfaceNKG2D
ligands was observed. Similar data were obtained with two other
strains of BCG. To investigate if BCG-exposed bladder cells were
also recognized by IL-2-activated NK cells through other recep-
tor–ligand interaction, degranulation assays were performed after
treating urothelial cells with BCG (Figure 4B). Surprisingly, only
minor changes were observed in the recognition of these cells.
Exposure of IL-2-Activated NK Cells to BCG did
not Affect Recognition of Bladder Cancer Cells
Previous reports showed that activation of PBMCs with BCG lead
to recognition of the urothelial cell line T24 (6, 7, 9). Next, we stud-
ied whether IL-2-stimulated NK cells could change their ability to
recognize a panel of bladder cancer cells after exposure to BCG
for four days. Unexpectedly, no substantial changes were observed
(Figure 5), indicating that, once IL-2 activated, NK cells from
healthy donors respond to bladder cancer cells independently of
the presence of BCG. Similarly, BCG treatment of freshly isolated,
purified NK cells had no effect on degranulation in response to
bladder cell lines (data not shown). These data suggest that the
importance of BCG for immunotherapy resides in the events that
lead toNK cell recruitment and activation, probably in the context
of other subpopulations of immune cells.
NK Cell Activation in the Presence of PBMCs and
BCG Achieves a Better Response to Bladder
Cancer Cells
In view of the previous experiments, where exposure to BCG
neither affected the recognition of bladder cell lines by IL-2-
activated NK cells nor led to activation of purified NK cells. We
next studied the phenotype and function of NK cells in cultures
of PBMCs cultured for 7 days either in the presence or absence of
BCG. After 1week in culture, only the NK cells that had been in
presence of BCG acquired an “activated” phenotype (as judged by
expression of CD69 and the IL-2-receptor α-chain CD25), while
NK cells in the control culture remained “resting” (Figure 6A).
In addition, BCG-activated NK cells degranulated better than
unstimulated NK cells against the panel of bladder cancer cells
(Figure 6B). Interestingly, BCG-activatedNK cells improved their
degranulation against all the bladder cancer cells, indicating that
this activation process is more efficient than just IL-2 activation.
These data indicate that crosstalk between immune cells stimu-
lated by the presence of BCG leads to an activation of NK cells
that improves their anti-tumor response.
The Percentage of Peripheral Blood NK Cells
Varies Among BCG-Treated Bladder Cancer
Patients but not with Treatment
Given that healthy activated NK cells respond to bladder cancer
cells via NKG2D, we next analyzed the expression of this receptor
in the NK cell compartment in peripheral blood of BCG-treated
cancer patients. The percentage of NK cells in peripheral blood of
a cohort of BCG-treated bladder cancer patients (N = 10, T0–T1
G3) was evaluated as part of a larger pilot study underway in the
laboratory. The expression of the NK marker CD56 was analyzed
by flow cytometry at different time points of the treatment for each
patient. Figure 7A shows the average of the NK cell percentage
for each patient during the first 9months of treatment. The SD of
these data reflect that the number of circulating NK cells did not
vary much for each patient with the treatment, instead, it was very
different from donor to donor. For comparison, bladder cancer
patients (N= 7, T1G2) receiving intravesical instillations ofMMC
were included and the distribution of NK cells in peripheral blood
of these control patients was similar to that of the BCG-treated
patients.
The levels of NKG2D on peripheral blood cells were also ana-
lyzed (Figure 7B). Although NKG2D expression by CD4+ T cells
has been reported in some diseases (35, 36), it was not observed in
these patients (data not shown). As expected, all CD8+ T cells and
NK cells were positive for NKG2D. However, different patterns
and values could be observed in the different patients. In general,
NKG2D was brighter in CD56bright cells, compared to CD56dim
cells (data not shown). Interestingly, while the variation during
treatment in the levels of NKG2D in PBMCs of MMC-treated
patients was not significant, the surface expression of NKG2D
by CD56bright and CD8+ cells of the BCG-treated patients did
decrease significantly over the course of the treatment. Inter-
estingly, while NKG2D expression decreased in the majority of
patients, a few patients did not follow this trend. NKp46 was
expressed mainly in CD56bright cells and, in most BCG-treated
patients, an increase that did not reach statistical significance in
the variation over the time of therapy of the expression of this
receptor was observed (Figure 7C).
Discussion
Natural killer cells had been suggested to play a role in the recog-
nition of J82 and T24 bladder tumor cell lines (6, 7, 9). However,
no systematic analysis of receptors and ligands involved in the
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FIGURE 6 | Effect of BCG exposure on NK cells in culture with other
lymphocytes. NK cells were incubated with BCG (1:1) for 7 days and their
activation phenotype was analyzed by flow cytometry analyzing surface CD25
and CD69 at various time points during the culture (A). PBMCs were used as
effectors in degranulation assays with the indicated bladder cancer cells and the
response by NK cells was evaluated gating in the CD3 CD56+ region. The
ability of NK cells previously cultured with BCG to respond to bladder cancer
cells was analyzed in degranulation experiments measuring surface LAMP-1
(CD107a) on the CD3 CD56+ population of PBMC (B). Data show three
experiments with different donors.
interaction between NK cells and a large panel of bladder tumor
cells has been reported. So, the first objective of this work was to
investigate the mechanism of recognition of bladder tumor cells
by IL-2-activated NK cells and the role of several NK receptors
mediating degranulation and cytoxicity toward these targets. We
describe that different bladder cancer cells express, at their cell
surface, a large number of ligands that can contribute to the
activation and inhibition of effector cells. In aggregate, all the
bladder cell lines studied express different NKG2D ligands and
the contribution of the NKG2D receptor was dominant.When the
degranulation experiments were compared with the phenotype
of bladder cancer cell lines, it could seem initially that surface
expression of NKG2D-L would not explain the differences in
NK cell activation. For example, UM-UC-3 and T24, both strong
stimulators for NK cell degranulation, expressed less NKG2D-L
than J82. However, the large amount of NKG2D-L on J82might be
counteracted partially by the presence of other inhibitory ligands,
among them,MHC-I. Interestingly, E-cadherin was found only in
those cell lines corresponding to lower grade tumors, while high-
grade cell lines did not have this molecule at the cell surface. This
could imply that E-cadherin could play an important role as a
negative modulator for the outcome of the interaction with low-
grade tumor cells. The functional consequences of the interaction
between KLRG1 and cadherins are still under study, but it is clear
that the receptor can modulate the immune response of both
NK and T cells (37, 38). However, blockade of KLRG1 on IL-
2-activated NK cells did not change the degranulation observed
(data not shown), ruling out the possibility that this interaction
would be important in this system. When the data from antibody
blocking experiments were analyzed, it was interesting to note
that, although blocking the NKp46 by itself does not have a major
effect on degranulation, the addition of NKp46 blocking mAb
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FIGURE 7 | Study of the NK cell compartment in a cohort of bladder
cancer patients treated with BCG. Blood samples were collected from
bladder cancer patients at different time points during treatment and
analyzed by flow cytometry. (A) Percentage of NK cells. The graph depicts
the average and SD of the percentage of CD3 CD56+ cells in lymphocytes
for each patient during the first 9months of treatment (nine samples for each
patient). Usual values in healthy donors are represented by a shadow. (B)
NKG2D. The mean fluorescence intensity of NKG2D was determined in
different lymphocyte populations of the patients at different times (12 time
points for BCG-treated patients; 4 time points for MMC-treated patients).
NKG2D MFI ranged between 30 and 80 in CD56bright, 30 and 70 for
CD56dim, and 40 and 70 in CD8+ T cells, within this patient cohort (data not
shown). The value of the NKG2D MFI from the initial () (before starting
treatment) and final samples () (9months for BCG; 3months for MMC)
were normalized for comparison and statistical analysis. The significance of
the variation between the initial and final sample was analyzed by t-test using
the Sidak–Bonferroni method. *Significant (p<0.05) ***significant (p<0.01).
(C) NKp46. The MFI of NKp46 was determined in the different lymphocyte
populations, normalized and analyzed by t-test using the Sidak–Bonferroni
method as in B. NKp46 MFI ranged between 2 and 18 in CD56bright and 1.5
and 10 for CD56dim, within this patient cohort (data not shown). The increase
in NKp46 MFI was not significant.
to NKG2D blockade often blocks NK recognition of the tumor
more strongly. This synergistic effect of NKp46 is consistent with
previous reports (39). In this context, similar to the panel of blad-
der tumor cell lines studied here, primary non-muscle invasive
bladder tumors have also been reported to express ligands for all
three natural cytotoxicity receptors (40). Yet, in our functional
assays, only NKp46 blocking mAbs had any effect on NK cell
recognition. Similarly, although the RT-112 and SW780 cell lines
expressedmore CD155 than the other cell lines, blocking DNAM-
1 with antibody did not have any clear effect on degranulation
suggesting that, at least in our system, the possible interaction
of CD155 with either DNAM-1 or CD96 (TACTILE), a receptor
expressed on resting NK cells that competes with CD226 and
could be a negative regulator (41), is not a critical influence on
NK recognition.
Thus, in summary, the main receptor involved in the recog-
nition of bladder cancer cells by NK cells is NKG2D, which is
present in all NK cells. However, in some cases, modulation of
the response by NKp46 and adhesion molecules can contribute to
immune recognition by NK cells in this system. NKG2D-specific
mAb blocked recognition of bladder cancer cells both in degran-
ulation and cytotoxicity experiments, however it is interesting to
note that some cell lines that did not trigger much degranulation
by the NK cells, were clearly dying in cytotoxicity experiments.
This could be related to death independent from lytic granules,
such as Fas–FasL, TNFα, or TRAIL-mediated interactions. In fact,
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it has been reported that a bladder cell line, T24, but not J82, is
susceptible to FasL-mediated lysis (4).
One of the major therapeutic strategies for bladder cancer
is the generation of an inflammatory/immune response to the
tumor by intravesical instillation of BCG. The mechanism of
action of this therapy is not fully understood, but several lines
of evidence suggest that NK cells play a key role in this response
(4–9). Thus, a second objective of the work presented here was
to test whether exposure of the bladder tumor cell lines to BCG
affected NK cell recognition. Our results show that BCG exposure
on bladder cancer cells affected neither NK cell degranulation
nor the expression of NKG2D ligands by these cells. NKG2D-
L are upregulated in cells exposed to Mtb (34, 42), pointing to
a difference between the two bacteria species. The data further
show that treating either IL-2-activatedNK cells or freshly isolated
NK cells with BCG did not affect the intensity of the response
against several bladder cancer cell lines. Interestingly, however,
stimulation of resting NK cells with BCG in PBMC cultures did
improve their anti-tumor response and revealed that their activa-
tion status is consistent with cytokine secretion. In particular, the
upregulation of CD25 indicates that BCG might be stimulating
the secretion of IL-2 presumably by T cells within the culture.
These data suggest that the particular manner to trigger NK cell
activationmight be a key factor in the treatment of bladder cancer
with BCG, and that the participation of other blood subpopula-
tions is necessary to achieve the appropriate NK response. More
experiments are required to understand in detail the process of
NK cell activation in the context of an ongoing immune response
against BCG.
Finally, the observation of significant changes in NKG2D
expression by NK cells in the blood of patients undergoing BCG
therapy supports the conclusion of the in vitro experiments that
NKG2D is a key receptor for immune recognition in bladder
cancer. Moreover, since the number of NK cells in patient
peripheral blood did not vary during the treatment of bladder
cancer with BCG it will be important to extend these observations
to study NK cell activation both locally and in peripheral blood.
It has been established that NKG2D is downmodulated after
interaction with its ligands (43), so the decrease in the receptor
could reflect that an interaction with cellular or soluble ligands
has occurred. These patient data also indicate that in-depth study
of the phenotype of these effector cells to evaluate the response
may lead to the identification of possible biomarkers of the NK
cell activation in each patient.
In conclusion, here we demonstrate that NK cells can rec-
ognize bladder tumor cells, mainly through NKG2D, and that
BCG exposure facilitates this anti-tumor response by modifying
the activation status of NK cells, not by modifying the receptors
directly involved in the cytotoxic response.
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